Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed the day trading at $2.06 up 10.16% from the previous closing price of $1.87. In other words, the price has increased by $10.16 from its previous closing price. On the day, 4.02 million shares were traded. IRWD stock price reached its highest trading level at $2.22 during the session, while it also had its lowest trading level at $1.88.
Ratios:
For a better understanding of IRWD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.18. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Gaskins Tammi L sold 1,316 shares for $0.84 per share. The transaction valued at 1,105 led to the insider holds 241,280 shares of the business.
John Minardo sold 7,754 shares of IRWD for $6,513 on Aug 11 ’25. The Chief Legal Officer now owns 400,378 shares after completing the transaction at $0.84 per share. On Aug 11 ’25, another insider, Martini Gregory S., who serves as the Chief Financial Officer of the company, sold 1,265 shares for $0.84 each. As a result, the insider received 1,063 and left with 182,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 334614304 and an Enterprise Value of 840431296. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08. Its current Enterprise Value per Revenue stands at 2.724 whereas that against EBITDA is 8.972.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.26, which has changed by -0.59871244 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 41.25%, while the 200-Day Moving Average is calculated to be 64.17%.
Shares Statistics:
Over the past 3-months, IRWD traded about 1.38M shares per day on average, while over the past 10 days, IRWD traded about 1453060 shares per day. A total of 162.43M shares are outstanding, with a floating share count of 156.35M. Insiders hold about 3.74% of the company’s shares, while institutions hold 89.67% stake in the company. Shares short for IRWD as of 1760486400 were 4702015 with a Short Ratio of 3.41, compared to 1757894400 on 5707969. Therefore, it implies a Short% of Shares Outstanding of 4702015 and a Short% of Float of 4.3899998.
Earnings Estimates
. The current rating of Ironwood Pharmaceuticals Inc (IRWD) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.12, with high estimates of $0.14 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.29 and $0.21 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.27, with 3.0 analysts recommending between $0.41 and $0.0.
Revenue Estimates
4 analysts predict $75.7M in revenue for. The current quarter. It ranges from a high estimate of $84.1M to a low estimate of $68.4M. As of. The current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 4 analysts are estimating revenue of $77.5M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 4 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $294.5M, while the lowest revenue estimate was $273.8M, resulting in an average revenue estimate of $279.38M. In the same quarter a year ago, actual revenue was $351.41MBased on 4 analysts’ estimates, the company’s revenue will be $264.12M in the next fiscal year. The high estimate is $300.9M and the low estimate is $225.8M.
